SURF News and Press, Surface Oncology Inc. From 12/17/20

Surface Oncology (SURF) inks an agreement with GlaxoSmithKline (GSK) for worldwide development and commercial rights to its preclinical program SRF813. Under the terms of the agreement, Surface Oncology will receive an upfront payment of $85M, potential milestone payments of $730M, ...

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG Surface Oncology to receive $85 million upfront payment CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF) today announced an agreement...

SURF has novel oncology assets and a decent amount of cash. Early data has shown some promise. There are rumours of buyout offers. For further details see: Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross...

Investors looking for stocks that can triple their money found what they were looking for in the biotech industry quite a few times this year. Some of those rockets are going to keep climbing, but most will eventually fizzle out. Surface Oncology (NASDAQ: SURF) and Replimmune ...

Surface Oncology (SURF) has announced that both of its lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), have achieved predefined criteria for advancement into combination and expansion stages of ongoing Phase 1 trials.Phase 1/1b trial of SRF617 was initiated in March for s...

Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose - limiting toxicities Detailed clinical data for each program to be presented at a medical confere...

The FDA has granted Fast Track designation to Surface Oncology's (SURF) SRF388 for the treatment of patients with hepatocellular carcinoma ((HCC)), or liver cancer, who have been previously treated with standard therapies.Fast Track status provides for more frequent interaction with the FDA r...

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

Surface Oncology (SURF): Q3 GAAP EPS of -$0.39.As of September 30, 2020, cash, cash equivalents and marketable securities were $102.5 million, compared to $105.2 million on December 31, 2019.The company continues to project that current cash and cash equivalents are sufficient to fund th...